A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

Summary

The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including screening.

Timeline

Start

2013-06

Primary completion

2013-07

Completion

2013-07

Drugs

Indications